Regulation and activities of amyloidogenic proteins APP and TGFBI in physiological and pathological protein aggregation
Regulation and activities of amyloidogenic proteins APP and TGFBI in physiological and pathological protein aggregation
批准号:
BB/W00707X/1
负责人:
Clive Wilson
金额:
$72.27万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Amyloidogenesis is the aggregation of normally soluble proteins into insoluble fibres. It is commonly observed in neurodegenerative disorders. For example, in Alzheimer's Disease, processed forms of a protein called APP self-aggregate to produce amyloid plaques in patients, and these plaques affect the survival of neurons. Similarly, defective forms of the TGFBI protein produce amyloid in the cornea and blindness. However, amyloid formation is not just pathological. For example, some hormones normally form inert amyloid structures called dense cores, which can be stored in cells prior to secretion.Combatting amyloid disease requires a better understanding of how amyloid formation is triggered and controlled. But studies in patients and in animals with Alzheimer's-like disease primarily focus on the end products of this process, plaques and memory loss. In fact, for proteins like APP and TGFBI, it has been unclear whether they are normally involved in protein aggregation or whether this is a uniquely pathological process. Large protein aggregates are typically only seen in disease, while normal protein aggregation generally involves the assembly of much smaller structures, making it difficult to follow this process using microscopy techniques suitable for living cells.We have been studying dense core formation in the fruit fly. Flies have equivalents of about 70% of human disease genes, including APP and TGFBI. It is often much easier to identify genes involved in biological processes and disease in flies and to watch these processes take place in living tissues. In fact, these animals are extensively used to study degenerative processes in Alzheimer's. We have identified a specific prostate-like cell in flies, the secondary cell, which makes dense cores that are over one thousand times larger than cores in other cells. This allowed us to follow the rapid formation of dense cores and how this is controlled for the first time in living tissues.Remarkably, we found that the fly equivalents of APP and TGFBI have complementary roles in making these dense cores. TGFBI is required for protein aggregation to take place, while APP ensures that micro-core structures coalesce together to make a single giant core. If a pathological form of APP is made in secondary cells, it changes the organisation of TGFBI in dense cores and stabilises them, so that they fail to disperse when secreted. Using the genetic approaches available in flies, we have already shown parallels between the control of dense core formation in secondary cells and plaque formation in humans, which both seem to involve small membranous droplets called exosomes.We will now study how APP and TGFBI work together to control dense core formation in secondary cells and how this process goes wrong when pathological versions of these amyloid proteins are made in these cells. We will also work out how altering the ways in which secreted proteins are guided through the secretory pathway changes these protein aggregation events in the cell, particularly focusing on whether pathological forms of APP or TGFBI behave differently to the normal proteins. Finally, we will test which of the large number of genes and cellular processes that have been suggested to play a role in Alzheimer's and neurodegeneration through studies in patients and animals are involved in normal and pathological APP and TGFBI aggregation in secondary cells. We will then work out precisely how they affect these processes.Our work will allow us to define how APP and TGFBI, two important amyloid proteins in disease, normally drive protein aggregation into insoluble dense cores. We will identify the genes that control this process and how pathological forms of APP and TGFBI interfere with this control. We will then be ideally positioned to collaborate with other researchers to determine which of these mechanisms is involved in amyloid disease in humans, and to develop approaches to block them.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pgen.1010979
发表时间:
2023-10
期刊:
PLoS genetics
影响因子:
4.5
作者:
[]
通讯作者:
Sex Peptide-dependent microcarrier signalling in reproduction
-
批准号:BB/W015455/1
-
项目类别:Research Grant
-
资助金额:$72.91万
-
财政年份:2022
-
负责人:Clive Wilson
-
依托单位:
Regulation of exosome heterogeneity and function
-
批准号:BB/R004862/1
-
项目类别:Research Grant
-
资助金额:$80.95万
-
财政年份:2018
-
负责人:Clive Wilson
-
依托单位:
Linking reproductive behaviour and dense core granule biogenesis in secondary cells of the Drosophila male reproductive system
-
批准号:BB/N016300/1
-
项目类别:Research Grant
-
资助金额:$66.13万
-
财政年份:2016
-
负责人:Clive Wilson
-
依托单位:
Regulation and functions of male-derived shed microvesicles in Drosophila reproduction
-
批准号:BB/L007096/1
-
项目类别:Research Grant
-
资助金额:$60.82万
-
财政年份:2014
-
负责人:Clive Wilson
-
依托单位:
Exosome signalling and cellular reprogramming in the Drosophila reproductive system
-
批准号:BB/K017462/1
-
项目类别:Research Grant
-
资助金额:$58.83万
-
财政年份:2013
-
负责人:Clive Wilson
-
依托单位:
国内基金
海外基金
美洲大蠊药材养殖及加工过程中化学成分动态变化与生物活性的相关性研究
-
批准号:81060329
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:肖培云
-
依托单位:
P-糖蛋白和CYP3A4活性对肾病患者合用非洛地平、环孢素前后药物代谢动力学影响研究
-
批准号:30772617
-
项目类别:面上项目
-
资助金额:8.0万元
-
批准年份:2007
-
负责人:王弘
-
依托单位: